Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients

Current medical treatment for inflammatory bowel disease (IBD) does not achieve 100% response rates, and a subset of refractory and severely ill patients have persistent active disease after being treated with all possible drug alternatives. The combination of two biological therapies (CoT) seems a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mas, Eduard Brunet, Calvo, Xavier Calvet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877715/
https://www.ncbi.nlm.nih.gov/pubmed/35207347
http://dx.doi.org/10.3390/jcm11041076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877715/
https://www.ncbi.nlm.nih.gov/pubmed/35207347
http://dx.doi.org/10.3390/jcm11041076

Ejemplares similares